Common use of Functional Studies Clause in Contracts

Functional Studies. To determine the function of novel proteins, both in vivo and in vitro models are utilized. In both cases the research involves two major approaches; firstly, administration of purified protein at varying doses and times of treatment, secondly, administration of an antisense oligonucleotide directed at the novel gene sequence to block expression of the protein product. Subsequently, a variety of metabolic parameters are measured and gene expression of key enzyme pathways determined. The availability of real-time PCR technology in our laboratories allows us to quickly and confidently quantitate changes in expression in tissue samples following protein treatment. Each phase of the research program is currently underway and running simultaneously; different genes identified are at various stages of development throughout the program. At the end of the research and development program, we will have identified a number of new genes involved in obesity development; we will have produced their protein products and further developed this research by determining the basic function of the novel protein in tissue culture systems and in whale animal studies. The result will be key lead compounds for further development by Lipha in Stage We currently have identified eight novel genes and these genes will proceed through various stages of the above research plan during 1999/2000. The development and progress achieved with each of these previously identified novel genes and new genes uncovered will be reported to the Autogen Scientific Advisory Board under the following Milestones-, 1. Identification of gene sequences up- or down-regulated in diabetic, non-diabetic, lean and obese animals. 2. Identification of full-gene sequence and confirmation of novel character.

Functional Studies. To determine the function of novel proteins, both in vivo and in vitro models are utilized. In both cases the research involves two major approaches; firstly, administration of purified protein at varying doses and times of treatment, secondly, administration of an antisense oligonucleotide directed at the novel gene sequence to block expression of the protein product. Subsequently, a variety of metabolic parameters are measured and gene expression of key enzyme pathways determined. The availability of real-time PCR technology in our laboratories allows us to quickly and confidently quantitate changes in expression in tissue samples following protein treatment. Each phase of the research program is currently underway and running simultaneously; different genes identified are at various stages of development throughout the program. At the end of the research and development program, we will have identified a number of new genes involved in obesity diabetes development; we will have produced their protein products and further developed this research by determining the basic function of the novel protein in tissue culture systems and in whale animal studies. The result will be key lead compounds for further development by Lipha in Stage 2. We currently have identified eight a pool of potential genes of which four are novel diabetes-related genes and these genes genes, and others as confirmed, will proceed through various stages of the above research plan during 1999/2000. The development and progress achieved with each of these previously identified novel genes navel gene and new genes uncovered will be reported to the Autogen Scientific Advisory Board established under the Autogen/Lipha Research and Licence Agreement under the following Milestones-,Milestones: 1. Identification of gene sequences up- or down-regulated in diabetic, non-diabetic, lean loan and obese animals. 2. Identification of full-gene sequence and confirmation of novel character.